Advanced search×

Blood lipid profiles and peripheral blood mononuclear cell cholesterol metabolism gene expression in patients with and without methotrexate treatment

Der-Yuan Chen, Hui-Min Chih, Joung-Liang Lan, Hsin-Yueh Chang, Wei-Wen Chen, and En-Pei Chiang

BMC Med 9(1):4 (2011) PMID 21232092

Methotrexate (MTX) is the most commonly prescribed disease-modifying antirheumatic drug (DMARD) in rheumatoid arthritis. ATP-binding cassette transporter-A1 (ABCA1) and 27-Hydroxylase (HY27) are known antiatherogenic proteins that promote cellular cholesterol efflux. In THP-1 macrophages, MTX can promote the reversal of cholesterol transport, limit foam cell formation and also reverse COX-2 inhibitor-mediated downregulation of ABCA1. Despite its antiatherogenic potential in vitro, the impact of clinical use of low-dose MTX on cholesterol metabolism in humans is unknown. Objective of the study was to examine whether clinical MTX use is associated with altered blood lipids and/or ABCA1/HY27 expressions.

DOI: 10.1186/1741-7015-9-4
Version: za2963e q8zab q8zb3 q8zcc q8zd3 q8ze5 q8zf5 q8zg8
PDF not found

Similar articles you may find interesting…

  1. Temporary [corrected] cerebral ischemia results in swollen astrocytic end-feet that compress microvessels and lead to delayed [corrected] fo...
    Umeo U Ito, Yoji Y Hakamata, ... Kiyomitsu K Oyanagi

    J Cereb Blood Flow Metab 31(1):328-38 (2011) PMID 20588315

    We examined the mechanisms underlying the abrupt onset of the focal infarction in disseminated selective neuronal necrosis (DSNN) after temporary ischemia. Stroke-positive animals were selected according to their stroke-index score during the first 10 minutes after left carotid occlusion performed...
  2. A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for st...
    Christos A Papadimitriou, Pavlos Papakostas, ... George Fountzilas

    BMC Med 9(1):10 (2011) PMID 21281463

    View PDF
  3. Lipotoxicity and steatohepatitis in an overfed mouse model for non-alcoholic fatty liver disease
    Ingrid C Gaemers, Jan M Stallen, ... Wouter H Lamers

    Biochimica et Biophysica Acta (BBA) - Molec... 1812(4):12 (2011) PMID 21216282

    The major risk factors for non-alcoholic fatty liver disease (NAFLD) are obesity, insulin resistance and dyslipidemia. The cause for progression from the steatosis stage to the inflammatory condition (non-alcoholic steatohepatitis (NASH)) remains elusive at present,. Aim of this stud...